Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Community-dwelling, over 55 years old, able to give full informed consent, willing to be randomized~* Able to perform a telephone interview~* Able to speak, read and understand English~* Potential volunteers on a statin drug, angiotensin converting enzyme inhibitor (ACE-I), angiotensin II receptor blocker (ARB), non-steroidal anti-inflammatory drug (NSAID), or Vitamin E supplement, are eligible but must be on a stable dose for at least 2 months~* Women must be post-menopausal, as defined by no menses for 12 months~* Must meet 3 of the 5 requirements for Metabolic Syndrome:~  * Waist measurement: greater than 102 cm for men and 88 cm for women~ * Fasting hypertriglyceridemia: 150 mg/dl (1.7 mmol/L) or higher~ * Low HDL cholesterol: less than 40 mg/dl (1.0 mmol/L) for men and 50 mg/dl (1.3 mmol/L) for women~ * Hypertension: higher than 130 mmHg systolic or 85 mmHg diastolic (average of 2 seated measurements) or currently using an antihypertensive medication~ * Elevated (untreated) fasting glucose: 100 mg/dl (5.6 mmol/L) or higher~* Meet the study's 4-step screening process for MCI (to rule out dementia)~Exclusion Criteria:~* Diagnosis of diabetes mellitus (DM), defined as: Fasting Blood Sugar 126 or higher, a history of known DM, or treatment with any glucose lowering medication~* Current diagnosis of dementia (or MMSE less than 24) or a neurological co-morbidity other than MCI that might affect cognition including: large vessel stroke, brain tumor, severe brain injury, multiple sclerosis, or Parkinson's disease~* Current diagnosis of depression assessed by a Centers for Epidemiologic Studies Depression Scale (CES-D) score of 36 or less~* Major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and/or cooperate fully with the protocol~* Significant cerebral vascular disease~* Modified Hachinski score greater than 4~* Pregnant, lactating or having child bearing potential~* Concomitant medications with significant cholinergic or anticholinergic effects or adverse effects on cognition including: antipsychotics, tricyclic antidepressants, anticonvulsants, sedative/hypnotics, anxiolytics, glucocorticoids (chronic or frequent intermittent), gingko biloba, NMDA receptor antagonists, cholinesterase inhibitors, strongly lipid soluble beta blockers (e.g., propranolol)~* Hormone replacement therapy (male or female)~* Visual/hearing impairment that would significantly impact the ability to undergo psychometric testing~* Significant medical illness or organ failure including hepatic or renal failure, unstable cardiac disease, or life expectancy less than 18 months~* Exercise-limiting conditions including: neuromuscular, joint/bone, cardiovascular, peripheral vascular, cerebrovascular or pulmonary disease; recent MI, pulmonary embolus, significant aortic stenosis; or exercise limiting obesity~* Untreated B12 deficiency or hypothyroidism (stable treatment for at least 3 months is allowable)~* Uncontrolled hypertension: over 160 mmHg systolic or 100 mmHg diastolic (stable treatment is allowable)~* Endurance exercise training more than twice a week for 20 minutes (at a level that produces sweating) consistently during the last 6 months~* Unstable weight in the last 6 months~* Increased risk for Pio toxicity including: a) baseline liver dysfunction (over 2.5xULN for AST, ALT); b) hematocrit less than 33% men or 30% women; c) problematic edema; or d) congestive heart failure NYHA class II or greater~* Stage 5 renal impairment (GFR less than 15 or dialysis)~* Already taking a TZD or other drug that would modify insulin resistance (e.g. metformin), or has taken a TZD in the past and experienced a significant adverse effect or allergy~* Currently taking any of following medications that may interact with Pio metabolism: atorvastatin at 80mg/day (lower doses are allowed), and medications with major CYP 3A4 inhibiting effects, such as nefazodone or systemic antifungal agents~* Participating in another clinical trial

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pioglitazone (Type: EXPERIMENTAL): Pioglitazone~30 - 45mg tablet daily for 6 months
- Endurance Exercise Training (Type: ACTIVE_COMPARATOR): Endurance Exercise Training (EET) Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching tablet sugar pill daily for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete